Literature DB >> 15210945

Acute neuroprotective synergy of erythropoietin and insulin-like growth factor I.

Murat Digicaylioglu1, Gwenn Garden, Sonia Timberlake, Lauren Fletcher, Stuart A Lipton.   

Abstract

Erythropoietin (EPO) and insulin-like growth factor I (IGF-I) are cytokines that inhibit neuronal apoptosis. However, their maximal antiapoptotic effect, even at high concentrations, is observed only when neurons are pretreated for several hours before insult. Here we show that simultaneous administration of EPO and IGF-I (EPO+IGF-I) eliminates the preincubation period required to prevent N-methyl-D-aspartate (NMDA)-induced apoptosis in cultured rat cerebrocortical neurons. The synergistic effect of EPO+IGF-I was mediated, at least in part, by activation of phosphatidylinositol 3-kinase (PI3-K). EPO+IGF-I synergistically activated Akt (protein kinase B), a downstream target of PI3-K, and prevented dephosphorylation of Akt. Overexpression of a dominant interfering form of Akt (dnAkt) abrogated EPO+IGF-I-mediated neuroprotection. EPO+IGF-I treatment did not prevent initial NMDA-induced caspase-3 activation, which was observed within 6 h of insult; however, EPO+IGF-I-treated neurons survived at least 2 days after NMDA insult. These cytokines prevented neuronal apoptosis downstream of caspase activation by facilitating association between X-linked inhibitor of apoptosis protein, an inhibitor of caspase proteolytic activity, and activated caspase-3. These results imply that EPO+IGF-I exert cooperative actions that afford acute neuroprotection via activation of the PI3-K-Akt pathway.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15210945      PMCID: PMC470763          DOI: 10.1073/pnas.0403172101

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  57 in total

Review 1.  IAP proteins: blocking the road to death's door.

Authors:  Guy S Salvesen; Colin S Duckett
Journal:  Nat Rev Mol Cell Biol       Date:  2002-06       Impact factor: 94.444

2.  Quantitative autoradiographic localization of [125I]insulin-like growth factor I, [125I]insulin-like growth factor II, and [125I]insulin receptor binding sites in developing and adult rat brain.

Authors:  S Kar; J G Chabot; R Quirion
Journal:  J Comp Neurol       Date:  1993-07-15       Impact factor: 3.215

3.  Erythropoietin therapy for acute stroke is both safe and beneficial.

Authors:  Hannelore Ehrenreich; Martin Hasselblatt; Christoph Dembowski; Lukas Cepek; Piotr Lewczuk; Michael Stiefel; Hans-Heino Rustenbeck; Norbert Breiter; Sonja Jacob; Friederike Knerlich; Matthias Bohn; Wolfgang Poser; Eckart Rüther; Michael Kochen; Olaf Gefeller; Christoph Gleiter; Thomas C Wessel; Marc De Ryck; Loretta Itri; Hilmar Prange; Anthony Cerami; Michael Brines; Anna-Leena Sirén
Journal:  Mol Med       Date:  2002-08       Impact factor: 6.354

4.  Neuroprotective effect of erythropoietin on hypoxic-ischemic brain injury in neonatal rats.

Authors:  Abdullah Kumral; Erdener Ozer; Osman Yilmaz; Mustafa Akhisaroglu; Necati Gokmen; Nuray Duman; Cagnur Ulukus; Sermin Genc; Hasan Ozkan
Journal:  Biol Neonate       Date:  2003

5.  Free insulin-like growth factor (IGF)-I and IGF binding proteins 2, 5, and 6 in spinal motor neurons in amyotrophic lateral sclerosis.

Authors:  Nadine Wilczak; Rob A I de Vos; Jacques De Keyser
Journal:  Lancet       Date:  2003-03-22       Impact factor: 79.321

6.  Erythropoietin prevents early and late neuronal demise through modulation of Akt1 and induction of caspase 1, 3, and 8.

Authors:  Zhao Zhong Chong; Shi-Hua Lin; Jing-Qiong Kang; Kenneth Maiese
Journal:  J Neurosci Res       Date:  2003-03-01       Impact factor: 4.164

7.  Phosphatidylinositol 3-kinase associates, via its Src homology 2 domains, with the activated erythropoietin receptor.

Authors:  J E Damen; A L Mui; L Puil; T Pawson; G Krystal
Journal:  Blood       Date:  1993-06-15       Impact factor: 22.113

8.  Recombinant human insulin-like growth factor I exerts a trophic action and confers glutamate sensitivity on glutamate-resistant cerebellar granule cells.

Authors:  P Calissano; M T Ciotti; L Battistini; C Zona; A Angelini; D Merlo; D Mercanti
Journal:  Proc Natl Acad Sci U S A       Date:  1993-09-15       Impact factor: 11.205

9.  A redox-based mechanism for the neuroprotective and neurodestructive effects of nitric oxide and related nitroso-compounds.

Authors:  S A Lipton; Y B Choi; Z H Pan; S Z Lei; H S Chen; N J Sucher; J Loscalzo; D J Singel; J S Stamler
Journal:  Nature       Date:  1993-08-12       Impact factor: 49.962

10.  Neurogenesis in explants from the walls of the lateral ventricle of adult bovine brain: role of endogenous IGF-1 as a survival factor.

Authors:  M Pérez-Martín; M Cifuentes; J M Grondona; F J Bermúdez-Silva; P M Arrabal; J M Pérez-Fígares; A J Jiménez; L M García-Segura; P Férnandez-Llebrez
Journal:  Eur J Neurosci       Date:  2003-01       Impact factor: 3.386

View more
  40 in total

1.  PINK1 enhances insulin-like growth factor-1-dependent Akt signaling and protection against apoptosis.

Authors:  Ravi S Akundi; Lianteng Zhi; Hansruedi Büeler
Journal:  Neurobiol Dis       Date:  2011-09-16       Impact factor: 5.996

Review 2.  The therapeutic potential of insulin-like growth factor-1 in central nervous system disorders.

Authors:  Jesse Costales; Alexander Kolevzon
Journal:  Neurosci Biobehav Rev       Date:  2016-01-15       Impact factor: 8.989

3.  The combination of insulin-like growth factor 1 and erythropoietin protects against ischemic spinal cord injury in rabbits.

Authors:  Kohji Utada; Kazuyoshi Ishida; Suguru Tohyama; Yutaka Urushima; Yoichi Mizukami; Atsuo Yamashita; Masato Uchida; Mishiya Matsumoto
Journal:  J Anesth       Date:  2015-05-24       Impact factor: 2.078

4.  Erythropoietin: a multimodal neuroprotective agent.

Authors:  Nadiya Byts; Anna-Leena Sirén
Journal:  Exp Transl Stroke Med       Date:  2009-10-21

Review 5.  New strategies for Alzheimer's disease and cognitive impairment.

Authors:  Kenneth Maiese; Zhao Zhong Chong; Jinling Hou; Yan Chen Shang
Journal:  Oxid Med Cell Longev       Date:  2009 Nov-Dec       Impact factor: 6.543

6.  Optimal neuroprotection by erythropoietin requires elevated expression of its receptor in neurons.

Authors:  Pascal E Sanchez; Raafat P Fares; Jean-Jacques Risso; Chantal Bonnet; Sandrine Bouvard; Marion Le-Cavorsin; Béatrice Georges; Colette Moulin; Amor Belmeguenai; Jacques Bodennec; Anne Morales; Jean-Marc Pequignot; Etienne-Emile Baulieu; Robert A Levine; Laurent Bezin
Journal:  Proc Natl Acad Sci U S A       Date:  2009-06-03       Impact factor: 11.205

7.  Safety of intravitreally administered recombinant erythropoietin (an AOS thesis).

Authors:  James C Tsai
Journal:  Trans Am Ophthalmol Soc       Date:  2008

Review 8.  Erythropoietin for infants with hypoxic-ischemic encephalopathy.

Authors:  Ronald J McPherson; Sandra E Juul
Journal:  Curr Opin Pediatr       Date:  2010-04       Impact factor: 2.856

Review 9.  Erythropoietin, forkhead proteins, and oxidative injury: biomarkers and biology.

Authors:  Kenneth Maiese; Jinling Hou; Zhao Zhong Chong; Yan Chen Shang
Journal:  ScientificWorldJournal       Date:  2009-10-02

10.  Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases.

Authors:  Douglas B Kell
Journal:  BMC Med Genomics       Date:  2009-01-08       Impact factor: 3.063

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.